Cangrelor-induced platelet inhibition was lower in STEMI versus non-STEMI patients and ticagrelor, while switching to oral P2Y12 inhibitors caused greater HRPR in non-STEMI patients.
Does cangrelor-induced platelet inhibition differ between patients with and without STEMI undergoing PCI?
Cangrelor provides less potent platelet inhibition in STEMI compared to non-STEMI patients and ticagrelor, while switching to oral agents poses higher HRPR risk in non-STEMI patients.
Absolute Event Rate: 0% vs 0%
BACKGROUND: Cangrelor is approved for oral P2Y12 inhibitor naïve patients undergoing percutaneous coronary intervention (PCI). Pharmacodynamic (PD) investigations in different clinical settings, using various assays have shown contrasting data in terms of entity of platelet inhibition and rates of high residual platelet reactivity (HRPR). We assessed the PD effects in patients with or without ST elevation myocardial infarction (STEMI) receiving cangrelor during PCI. METHODS: The PharmacOdynaMic effects of cangrelor in PatiEnts wIth acute or chronIc coronary syndrome undergoing percutaneous coronary intervention (POMPEII) registry (NCT04790032) is an investigator-initiated, prospective study assessing PD at 4 time-points with 3 assays. RESULTS: From March 2021 to June 2024, 126 patients naïve from oral P2Y12 inhibitors underwent PCI with cangrelor (32 with STEMI and 94 without NSTE-ACS=30, CCS=64). All STEMI patients switched from cangrelor to ticagrelor, while most patients without STEMI switched to clopidogrel. Inhibition of platelet aggregation (IPA%) during cangrelor infusion was lower in patients with STEMI compared with those without STEMI (LTA 20-μM-ADP 51.5±16.2% vs 59.7±16.2%; p=0.017). Conversely, after switching from cangrelor to an oral P2Y12 inhibitor, IPA was greater in patients with STEMI compared to those without STEMI. Rates of HRPR were consistent with lower platelet inhibition in STEMI during cangrelor and greater after its discontinuation compared with patients without STEMI. Within STEMI patients, cangrelor-induced IPA was lower compared with ticagrelor-induced IPA (p=0.036). CONCLUSIONS: Cangrelor-induced platelet inhibition was lower in patients with STEMI compared to those without STEMI, and was lower than that induced by ticagrelor among STEMI patients. The switch from cangrelor to an oral P2Y12 inhibitor exposed patients without STEMI to greater HRPR compared to those with STEMI.
Gargiulo et al. (Mon,) reported a other. Cangrelor-induced platelet inhibition was lower in STEMI versus non-STEMI patients and ticagrelor, while switching to oral P2Y12 inhibitors caused greater HRPR in non-STEMI patients.